Psychotropic Panel Genetic Testing Antidepressants | Personalized Genetic Testing

PSYCHOTROPIC PANEL
Genetic Testing for Psychiatric Medications

Ready to get started or want to learn more? Fill out the form below.

Personalized Genetic Testing provides an invaluable service to physicians and patients throughout the U.S.

Thousands of Tests Performed

Providing doctors with the information needed to determine the best medicines and treatments for each of their patients.

20+ Years Experience

Experience in biotechnology, pharmaceutical, hematology, flow cytometry, clinical molecular biology, immunology, and chemistry industries.

Fast 5-Day Turnaround

Using the latest technologies from the leaders in the industry, our process is 3 times faster than competitor’s analysis methods.

Accurate Reporting

Through Coriell Institute, backed by over 60 years of research experience providing the quality control required for validation in pharmacogenetics testing.

The PGT Psychotropic Panel supports doctors in determining the appropriate medications and doses for the treatment of depression, anxiety, and ADHD.

PGT Analgesic Panel provides genetic results for:

Psychotropic Panel:

CYP2D6 Is involved in the metabolism of more than 70 drugs, including many antidepressants and antipsychotics. Based on the CYP2D6 DNA testing for antidepressants, a patient’s doses can be adjusted to minimize drug toxicity.
CYP2C19 Is involved in the metabolism of a wide range of anti-depressants and benzodiazepines.
CYP1A2 Is primarily responsible for clozapine metabolism. The genetic studies of clozapine drug response are supported by the identification of multiple functional variants in CYP1A2,  with well-defined effects on clozapine metabolism. CYP1A2 genetic lab testing can assist in determining the correct doses of this medication.
CYP3A4 Plays an important role also in psycho- pharmacotherapy as it contributes to the biotransformation of various antidepressants, antipsychotics,  benzodiazepines.
DRD2/ANKK1 The D2 dopamine receptor encoded from DRD2 is the primary target of most antipsychotic medications. The ankyrin repeat and kinase domain containing 1 gene (ANKK1) is located 10 kb from DRD2  and has been associated with tardive dyskinesia (TD). DRD2 genetic testing can assist in determining dosing for these medications.

Genetic testing for antidepressant response, such as a cytochrome P450 test, may speed up the identification of medications that are more likely to be better processed by your body and is usually done when antidepressant treatments are not successful.

 

ADHD Panel:

CYP2B6 Responsible for the metabolism of the most active metabolite of bupropion
CYP2D6 Shown to have a significant effect on the body’s ability to metabolize atomoxetine
COMT An enzyme that degrades dopamine and norepinephrine, primarily in the prefrontal cortex of the brain a pharmacodynamic gene which has been implicated in the therapeutic response of patients taking stimulant medications (amphetamines) and some antipsychotics.
PGT Psychotropic Panel can help define the appropriateness and dosage of many of these prescribed drugs including:
Therapeutic Class Name of Drug
Antipsychotics Aripiprazole (Abilify®)
Aripiprazole (Abilify®)
Haloperidol (Haldol®)
Olanzapine (Zalasta®)
Quetiapine
Risperidone (Risperdal®)
Zuclopenthixol (Clopixol®)
Thioridazine (Mellaril®)
Anticonvulsants Clozaban (Onfi®)
Phenytoin( Dilantin®)
Antidementia Donepezil (Aricept®)
Selective Serotonin
Reuptake Inhibitors (SSRIs)
Citalopram (Celexa®)
Fluvoxamine (Luvox®)
Escitalopram (Lexapro®)
Fluoxetine (Prozac®)
Paroxetine (Paxil®)
Venlafaxine (Effexor®)
 Anti-ADHD Atomoxetine(Strattera®)
Antidepressants Amitriptyline (Elavil®)
Clomipramine (Anafranil®)
Desipramine (Norpramin®)
Doxepin (Deptran®)
Imipramine (Tofranil®)
Protriptyline (Vivactil®)
Trimipramine (Surmontil®)
Smoking Cessation Agents Bupropion (Wellbutrin®)